title: Effects of anti-VEGF agents on rat retinal Müller glial cells.
abstract: OBJECTIVE
  To evaluate the effects of an anti-rat vascular endothelial growth factor antibody (ARVA) and bevacizumab (Avastin) on rat retinal Müller glial cells (RMGCs) in vivo and in vitro.
  
  
  METHODS
  Rat RMGCs were identified and cultivated, and were then treated with bevacizumab (0.1, 0.25, and 1 mg/ml), ARVA (0.1, 0.5, and 1 microg/ml), or 1 mg/ml of rat immunoglobulin G (IgG) for 12, 24, 48, and 72 h. The numbers of viable RMGCs were determined using a trypan blue dye exclusion assay and a methyl thiazolyl tetrazolium colorimetric assay. In the in vivo study, the rats received intravitreal injections of 5 microl bevacizumab (3.75 mg/ml), ARVA (15 microg/ml), and rat IgG (1 mg/ml). The electroretinogram was recorded. Seven days after the injections, histopathologic changes and glial fibrillary acidic protein expression of RMGCs in the retina were analyzed by immunohistochemistry with hematoxylin-eosin and fluorescent staining.
  
  
  RESULTS
  After exposure to bevacizumab at various concentrations for various periods of time, the stained cell numbers and optical density values of mitochondrial dehydrogenase activity of RMGCs had no significant differences (p>0.05) from those of the control group and IgG medium. In the stained cells, ARVA demonstrated a dose-dependent increase. Compared with those treated for 12 and 24 h, the increase of stained cells treated with 0.5 and 1 microg/ml ARVA at 48 and 72 h was very significant (p<0.01). The optical densities of RMGCs exposed to 0.5 and 1 microg/ml of ARVA at 48 and 72 h were significantly lower than cells exposed to a fresh culture medium (p<0.01). The histology of both treated and control eyes after intravitreal injection was similar and showed no anatomic signs of toxicity. There were no obvious glial fibrillary acidic protein upregulations of RMGCs in all groups. The scotopic electroretinogram responses to flashes of light in the control and treated eyes had similar b-wave amplitudes.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab and ARVA had no short-term, direct retinal toxicity in rats. Bevacizumab exerts no inhibition on rat RMGCs, while ARVA at higher doses (over 0.5 microg/ml) may be harmful to the growth of RMGCs.
authors.affiliation: Bayi hospital, Department of ophthalmology, Yang Gongjin, Nanjing, Jiangsu, China. greatrobin@163.com
authors.forename: Bin
authors.initials: B
authors.lastname: Guo
authors.forename: Yingli
authors.initials: Y
authors.lastname: Wang
authors.forename: Yannian
authors.initials: Y
authors.lastname: Hui
authors.forename: Xinguang
authors.initials: X
authors.lastname: Yang
authors.forename: Qinhua
authors.initials: Q
authors.lastname: Fan
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D000906:Antibodies / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002452:Cell Count; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004596:Electroretinography; D056965:Injections, Intraocular; D009457:Neuroglia / Q000166:cytology / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D012160:Retina / Q000166:cytology* / Q000502:physiology; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
references.citation: J Neurophysiol. 1980 May;43(5):1355-66
references.pmid: 6246222
references.citation: Retina. 2006 Nov-Dec;26(9):1006-13
references.pmid: 17151487
references.citation: Invest Ophthalmol Vis Sci. 2010 Jun;51(6):3216-25
references.pmid: 20042644
references.citation: Exp Cell Res. 2004 Sep 10;299(1):68-78
references.pmid: 15302574
references.citation: Cardiovasc Hematol Agents Med Chem. 2007 Apr;5(2):147-54
references.pmid: 17430137
references.citation: Cerebrovasc Dis. 2006;21 Suppl 2:9-20
references.pmid: 16651810
references.citation: Neuroreport. 2004 Jul 19;15(10):1633-7
references.pmid: 15232297
references.citation: Trans Am Ophthalmol Soc. 2003;101:183-9; discussion 189
references.pmid: 14971576
references.citation: Retina. 2006 Mar;26(3):257-61
references.pmid: 16508423
references.citation: Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1844-52
references.pmid: 17389520
references.citation: Ophthalmol Clin North Am. 2006 Sep;19(3):335-44
references.pmid: 16935208
references.citation: Clin Exp Optom. 2005 May;88(3):132-45
references.pmid: 15926876
references.citation: Eye (Lond). 2010 Mar;24(3):497-505
references.pmid: 20057511
references.citation: Arch Ophthalmol. 2005 Apr;123(4):509-16
references.pmid: 15824225
references.citation: Rev Neurosci. 2004;15(4):293-307
references.pmid: 15526553
references.citation: J Neurochem. 2004 Oct;91(1):167-75
references.pmid: 15379897
references.citation: Retina. 2008 Jan;28(1):46-55
references.pmid: 18185137
references.citation: Clin Ophthalmol. 2008 Jun;2(2):339-46
references.pmid: 19668725
references.citation: Retina. 2009 Sep;29(8):1062-6
references.pmid: 19734760
references.citation: Brain Res. 2003 Apr 18;969(1-2):195-204
references.pmid: 12676380
references.citation: Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1601-8
references.pmid: 19597740
references.citation: Prog Retin Eye Res. 2006 Jul;25(4):397-424
references.pmid: 16839797
references.citation: Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1971-80
references.pmid: 10845624
references.citation: Br J Ophthalmol. 2006 Oct;90(10):1316-21
references.pmid: 16723358
references.citation: J Biol Chem. 2006 Mar 10;281(10):6625-31
references.pmid: 16373345
references.citation: Retina. 2006 Oct;26(8):882-8
references.pmid: 17031287
references.citation: Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):819-24
references.pmid: 20169356
references.citation: Am J Ophthalmol. 2006 Jul;142(1):162-4
references.pmid: 16815270
references.citation: Diabetes. 1998 May;47(5):815-20
references.pmid: 9588455
references.citation: Health Technol Assess. 2008 May;12(16):iii-iv, ix-201
references.pmid: 18462575
references.citation: Am J Health Syst Pharm. 2004 Nov 1;61(21 Suppl 5):S21-6
references.pmid: 15552623
references.citation: Retina. 2006 Jul-Aug;26(6 Suppl):S71-9
references.pmid: 16832305
references.citation: Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1837-42
references.pmid: 17347807
references.citation: Br J Ophthalmol. 2007 Sep;91(9):1230-3
references.pmid: 17475701